[DLys6]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo

International Journal of Cancer

Volumn 129, Issue 7, 2011, Pages 1611-1623

  Aggarwal, S ^a   Ndinguri, M W ^b,d   Solipuram, R ^a   Wakamatsu, N ^c   Hammer, R P ^b,e   Ingram, D ^a   Hansel, W ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e New England Peptide   (United States)

Author keywords

DLys6 LHRH curcumin; curcumin; luteinizing hormone releasing hormone receptor; pancreatic cancer; tumor growth inhibition

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE]; GONADORELIN[6 DEXTRO LYSINE] CURCUMIN CONJUGATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; FEMALE; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RECEPTORS, LHRH; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960922175     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26132     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Discher DE, Eisenberg A,. Polymer vesicles. Science 2002; 297: 967-73. (Pubitemid 34856022)
3. Torchilin VP,. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv Drug Deliv Rev 2002; 54: 235-52. (Pubitemid 34230444)
4. Leuschner C, Hansel W,. Membrane disrupting lytic peptides for cancer treatments. Curr Pharm Des 2004; 10: 2299-310. (Pubitemid 38855038)
5. David A, Kopeckova P, Minko T, Rubinstein A, Kopecek J,. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells. Eur J Cancer 2004; 40: 148-57. (Pubitemid 37542327)
6. Wirth M, Gerhardt K, Wurm C, Gabor F,. Lectin-mediated drug delivery: influence of mucin on cytoadhesion of plant lectins in vitro. J Control Release 2002; 79: 183-91. (Pubitemid 34164172)
7. Mao W, Luis E, Ross S, Silva J, Tan C, Crowley C, Chui C, Franz G, Senter P, Koeppen H, Polakis P,. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res 2004; 64: 781-8. (Pubitemid 38176871)
8. Schally AV, Nagy A,. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999; 141: 1-14. (Pubitemid 29370830)
9. Grundker C, Gunthert AR, Westphalen S, Emons G,. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 2002; 146: 1-14. (Pubitemid 34126412)
10. Fekete M, Wittliff JL, Schally AV,. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 1989; 3: 137-47. (Pubitemid 20199263)
11. Srkalovic G, Schally AV, Wittliff JL, Day TG, Jr. , Jenison EL,. Presence and characteristics of receptors for [D-Trp6] luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. Int J Oncol 1998; 12: 489-98. (Pubitemid 28097966)
12. Emons G, Ortmann O, Schulz KD, Schally AV,. Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells. Trends Endocrinol Metab 1997; 8: 355-62. (Pubitemid 28034420)
13. Liebow C, Lee MT, Kamer AR, Schally AV,. Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous and autologous receptor-stimulated tyrosine phosphorylation. Proc Natl Acad Sci USA 1991; 88: 2244-8. (Pubitemid 21916392)
14. Friess H, Kleeff J, Korc M, Buchler MW,. Molecular aspects of pancreatic cancer and future perspectives. Dig Surg 1999; 16: 281-90. (Pubitemid 29376329)
15. Hansel W, Enright F, Leuschner C,. Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo. Mol Cell Endocrinol 2007; 260-262: 183-9. (Pubitemid 44792362)
16. Hansel W, Leuschner C, Enright F,. Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases. Mol Cell Endocrinol 2007; 269: 26-33. (Pubitemid 46483829)
17. Leuschner C, Hansel W,. Targeting breast and prostate cancers through their hormone receptors. Biol Reprod 2005; 73: 860-5. (Pubitemid 41507487)
18. Adams LS, Phung S, Yee N, Seeram NP, Li L, Chen S,. Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway. Cancer Res 2010; 70: 3594-605.
19. Adams LS, Zhang Y, Seeram NP, Heber D, Chen S,. Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro. Cancer Prev Res (Phila) 2010; 3: 108-13.
20. Henning SM, Seeram NP, Zhang Y, Li L, Gao K, Lee RP, Wang DC, Zerlin A, Karp H, Thames G, Kotlerman J, Li Z, et al. Strawberry consumption is associated with increased antioxidant capacity in serum. J Med Food 2010; 13: 116-22.
21. Ray RB, Raychoudhuri A, Steele R, Nerurkar P,. Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res 2010; 70: 1925-31.
22. Kuo ML, Huang TS, Lin JK,. Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. Biochim Biophys Acta 1996; 1317: 95-100.
23. Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB,. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer 2004; 111: 679-92. (Pubitemid 39062889)
24. Huang MT, Lou YR, Xie JG, Ma W, Lu YP, Yen P, Zhu BT, Newmark H, Ho CT,. Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenz[a]anthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice. Carcinogenesis 1998; 19: 1697-700. (Pubitemid 28441876)
25. Kim JM, Araki S, Kim DJ, Park CB, Takasuka N, Baba-Toriyama H, Ota T, Nir Z, Khachik F, Shimidzu N, Tanaka Y, Osawa T, et al. Chemopreventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1,2-dimethylhydrazine initiation. Carcinogenesis 1998; 19: 81-5. (Pubitemid 28376829)
26. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB,. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 2006; 69: 195-206. (Pubitemid 43048906)
27. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB,. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007; 67: 3853-61. (Pubitemid 46762173)
28. Aggarwal S, Takada Y, Mhashilkar AM, Sieger K, Chada S, Aggarwal BB,. Melanoma differentiation-associated gene-7/IL-24 gene enhances NF-kappa B activation and suppresses apoptosis induced by TNF. J Immunol 2004; 173: 4368-76. (Pubitemid 39280665)
29. Dharap SS, Minko T,. Targeted proapoptotic LHRH-BH3 peptide. Pharm Res 2003; 20: 889-96. (Pubitemid 36628435)
30. Ndinguri MW, Solipuram R, Gambrell RP, Aggarwal S, Hammer RP,. Peptide targeting of platinum anti-cancer drugs. Bioconjug Chem 2009; 20: 1869-78.
31. Syng-Ai C, Kumari AL, Khar A,. Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2. Mol Cancer Ther 2004; 3: 1101-8. (Pubitemid 39295007)
32. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G,. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 2003; 442: 444-52. (Pubitemid 36718311)
33. Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S, Sinko PJ, Stein S, Farmanfarmaian A, Minko T,. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci USA 2005; 102: 12962-7. (Pubitemid 41279472)
34. Imai A, Horibe S, Takagi A, Ohno T, Tamaya T,. Frequent expression of Fas in gonadotropin-releasing hormone receptor-bearing tumors. Eur J Obstet Gynecol Reprod Biol 1997; 74: 73-8. (Pubitemid 27272187)
35. Imai A, Takagi A, Horibe S, Takagi H, Tamaya T,. Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells. Int J Oncol 1998; 13: 97-100. (Pubitemid 28267501)
36. Imai A, Takagi A, Horibe S, Takagi H, Tamaya T,. Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death. J Clin Endocrinol Metab 1998; 83: 427-31. (Pubitemid 28496517)
37. Greenwald RB, Zhao H, Reddy P,. Synthesis, isolation, and characterization of 2′-paclitaxel glycinate: an application of the Bsmoc protecting group. J Org Chem 2003; 68: 4894-6. (Pubitemid 36682716)
38. Khandare JJ, Chandna P, Wang Y, Pozharov VP, Minko T,. Novel polymeric prodrug with multivalent components for cancer therapy. J Pharmacol Exp Ther 2006; 317: 929-37. (Pubitemid 43764094)
39. Szende B, Srkalovic G, Schally AV, Lapis K, Groot K,. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression. Cancer 1990; 65: 2279-90. (Pubitemid 20164836)
40. Lee MT, Liebow C, Kamer AR, Schally AV,. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Proc Natl Acad Sci USA 1991; 88: 1656-60. (Pubitemid 21916284)
41. Hansel W, Leuschner C, Gawronska B, Enright F,. Targeted destruction of prostate cancer cells and xenografts by lytic peptide-betaLH conjugates. Reprod Biol 2001; 1: 20-32.
42. Ko SY, Guo H, Barengo N, Naora H,. Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E. Clin Cancer Res 2009; 15: 4336-47.
43. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE,. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005; 11: 7490-8. (Pubitemid 41507710)
44. Chauhan DP,. Chemotherapeutic potential of curcumin for colorectal cancer. Curr Pharm Des 2002; 8: 1695-706. (Pubitemid 34846196)
45. Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, Wang Z, Philip PA, Sarkar FH,. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010; 70: 3606-17.
46. Subramaniam D, May R, Sureban SM, Lee KB, George R, Kuppusamy P, Ramanujam RP, Hideg K, Dieckgraefe BK, Houchen CW, Anant S,. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Cancer Res 2008; 68: 1962-9. (Pubitemid 351416583)
47. Furui T, Imai A, Tamaya T,. Intratumoral level of gonadotropin-releasing hormone in ovarian and endometrial cancers. Oncol Rep 2002; 9: 349-52.
48. Kovacs M, Schally AV, Nagy A, Koppan M, Groot K,. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1997; 94: 1420-5. (Pubitemid 27087866)
49. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21: 2895-900.
50. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R,. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491-9.